Finalists from the 2019 PharmaTimes Clinical Researcher of the Year – The Americas reveal insight into their experience with the competition.
News
New NHS DNA test could ‘rapidly diagnose’ rare illnesses in babies
“Whole exome sequencing” can double the chance of a diagnosis and reveal what is wrong with patients in days rather than weeks
Incyte JAK1 inhibitor misses the mark in GVHD trial
Despite the setback, the company says that it will continue to study the role of JAK inhibition in chronic GVHD, and in the prophylactic setting.
MHRA updates Dysport license to include upper limb spasticity in children
The treatment is now the first and only botulinum toxin in the UK approved for the treatment of paediatric spasticity in both upper and lower limbs.
Sandoz opens new UK HQ
The new Surrey-based site will be the centre of the company’s UK operations, which encompasses a range of operational functions.
Lynparza bags FDA approval for pancreatic cancer
In a trial the drug nearly doubled the time that patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death
Could AI help detect breast cancer?
An artificial intelligence algorithm has outperformed both historical decisions made and the decisions of six expert radiologists.
NHS migraine kit to prevent ‘thousands’ of hospital stays
The number of admissions to hospitals in England for headaches and migraines has increased by 14% over the last five years.
Durect abandons DUR-928 after trial hiccup
The drug didn’t show any clinical benefit in any of the trial’s primary or secondary analyses.
NICE refuses Akcea’s Waylivra
The FCS drug was granted a marketing authorisation in May 2019 by the European Commission.
Vaccitech, CR UK link up to develop NSCLC drug
Cancer Research UK will sponsor and manage a Phase I/IIa clinical trial of the drug in combination with current standard of care and first-line treatment
NHS diabetes drive sees public lose ‘weight of 43 ambulances’
89,604 people have now finished the programme, marking the service as a world first of its kind to have achieved a full national roll-out.
Late-stage success for experimental migraine drug
The results support the filing of a New Drug Application (NDA) for Axsome’s AXS-07 in the acute treatment of migraine.
‘Half’ the current chemo could prevent testicular cancer returning
Testicular cancer is the most common cancer affecting young men, with many patients being diagnosed in their twenties or thirties.
Tecentriq hit with draft NICE rejection
The UK watchdog says that the “long-term benefit on overall survival is uncertain”.
